INFOGRAPHIC: A US biotech IPO surge? Data are mixed

Many people argue that the surge in initial public offerings by biotechnology companies suggests a bubble in danger of imminent explosion, but is the industry's IPO market really surging? It depends on how you interpret the numbers related to first-time stock offerings so far in 2014 versus 2015.

Many people argue that the surge in initial public offerings by biotechnology companies suggests a bubble in danger of imminent explosion, but is the industry's IPO market really surging? It depends on how you interpret the numbers related to first-time stock offerings so far in 2014 versus 2015.

On the one hand, only 29 drug developers launched IPOs in the US during the first half of this year,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip